p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition

被引:61
作者
Ji, Zhenyu [1 ,3 ]
Njauw, Ching Ni [1 ]
Taylor, Michael [1 ]
Neel, Victor [1 ]
Flaherty, Keith T. [2 ]
Tsao, Hensin [1 ,2 ,3 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA
关键词
HUMAN-MALIGNANT MELANOMA; AZD6244; ARRY-142886; TUMOR SUPPRESSION; CELL-LINE; MDM2; MUTATIONS; GENE; APOPTOSIS; PATHWAY; CANCER;
D O I
10.1038/jid.2011.313
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100227 [皮肤病学];
摘要
Oncogenesis reflects an orchestrated interaction between misguided growth signals. Although much effort has been launched to pharmacologically disable activated oncogenes, one sidelined approach is the restoration of tumor suppressive signals. As TP53 is often structurally preserved, but functionally crippled, by CDKN2A/ARF loss in melanoma, rescue of p53 function represents an attractive point of vulnerability in melanoma. In this study, we showed that both p53 protein and activity levels in melanoma cells were strongly induced by nutlin-3, a canonical HDM2 antagonist. Among a test panel of 51 cell lines, there was a marked reduction in melanoma viability that was directly linked to TP53 status. Moreover, we also found that the melanoma growth suppression mediated by mitogen-activated protein kinase/extracellular signal-regulated kinase inhibition was potentiated by HDM2 antagonism. These results provide fundamental insights into the intact p53 circuitry, which can be restored through small molecule inhibitors and potentially deployed for therapeutic gain.
引用
收藏
页码:356 / 364
页数:9
相关论文
共 35 条
[1]
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers [J].
Adjei, Alex A. ;
Cohen, Roger B. ;
Franklin, Wilbur ;
Morris, Clive ;
Wilson, David ;
Molina, Julian R. ;
Hanson, Lorelei J. ;
Gore, Lia ;
Chow, Laura ;
Leong, Stephen ;
Maloney, Lara ;
Gordon, Gilad ;
Simmons, Heidi ;
Marlow, Allison ;
Litwiler, Kevin ;
Brown, Suzy ;
Poch, Gregory ;
Kane, Katie ;
Haney, Jerry ;
Eckhardt, S. Gail .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2139-2146
[2]
MUTATION AND EXPRESSION OF THE P53 GENE IN HUMAN-MALIGNANT MELANOMA [J].
ALBINO, AP ;
VIDAL, MJ ;
MCNUTT, NS ;
SHEA, CR ;
PRIETO, VG ;
NANUS, DM ;
PALMER, JM ;
HAYWARD, NK .
MELANOMA RESEARCH, 1994, 4 (01) :35-45
[3]
TRANSFORMING RAS GENES FROM HUMAN-MELANOMA - A MANIFESTATION OF TUMOR HETEROGENEITY [J].
ALBINO, AP ;
LESTRANGE, R ;
OLIFF, AI ;
FURTH, ME ;
OLD, LJ .
NATURE, 1984, 308 (5954) :69-72
[4]
LACK OF ALLELIC DELETION AND POINT MUTATION AS MECHANISMS OF P53 ACTIVATION IN HUMAN-MALIGNANT MELANOMA [J].
CASTRESANA, JS ;
RUBIO, MP ;
VAZQUEZ, JJ ;
IDOATE, M ;
SOBER, AJ ;
SEIZINGER, BR ;
BARNHILL, RL .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (04) :562-565
[5]
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].
Chapman, Paul B. ;
Hauschild, Axel ;
Robert, Caroline ;
Haanen, John B. ;
Ascierto, Paolo ;
Larkin, James ;
Dummer, Reinhard ;
Garbe, Claus ;
Testori, Alessandro ;
Maio, Michele ;
Hogg, David ;
Lorigan, Paul ;
Lebbe, Celeste ;
Jouary, Thomas ;
Schadendorf, Dirk ;
Ribas, Antoni ;
O'Day, Steven J. ;
Sosman, Jeffrey A. ;
Kirkwood, John M. ;
Eggermont, Alexander M. M. ;
Dreno, Brigitte ;
Nolop, Keith ;
Li, Jiang ;
Nelson, Betty ;
Hou, Jeannie ;
Lee, Richard J. ;
Flaherty, Keith T. ;
McArthur, Grant A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516
[6]
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method [J].
Chou, Ting-Chao .
CANCER RESEARCH, 2010, 70 (02) :440-446
[7]
Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[8]
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel [J].
Haass, Nikolas K. ;
Sproesser, Katrin ;
Nguyen, Thiennga K. ;
Contractor, Rooha ;
Medina, C. Angelica ;
Nathanson, Katherine L. ;
Herlyn, Meenhard ;
Smalley, Keiran S. M. .
CLINICAL CANCER RESEARCH, 2008, 14 (01) :230-239
[9]
Ultraviolet radiation and melanoma: A systematic review and analysis of reported sequence variants [J].
Hocker, Thomas ;
Tsao, Hensin .
HUMAN MUTATION, 2007, 28 (06) :578-588
[10]
Melanoma Genetics and Therapeutic Approaches in the 21st Century: Moving from the Benchside to the Bedside [J].
Hocker, Thomas L. ;
Singh, Meena K. ;
Tsao, Hensin .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2008, 128 (11) :2575-2595